A Two-Arm, Open-Label, Standard of Care Control Evaluation of Ferric Citrate for the Transition From Chronic Kidney Disease Stage 4/5 to Chronic Kidney Stage 5D
Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 09 Feb 2018
At a glance
- Drugs Ferric citrate (Primary)
- Indications Hyperphosphataemia; Iron deficiency anaemia
- Focus Therapeutic Use
- 16 Aug 2017 Planned End Date changed from 1 Sep 2017 to 1 Mar 2018.
- 16 Aug 2017 Planned primary completion date changed from 1 Sep 2017 to 1 Dec 2017.
- 16 Aug 2017 Status changed from recruiting to active, no longer recruiting.